Centogene N.V. (CNTG)
NASDAQ: CNTG · IEX Real-Time Price · USD
0.520
-0.001 (-0.10%)
At close: Jul 19, 2024, 4:00 PM
0.530
+0.010 (1.92%)
Pre-market: Jul 22, 2024, 6:50 AM EDT
Centogene Revenue
In the year 2023, Centogene had annual revenue of $53.93M with 6.78% growth.
Revenue (ttm)
$53.93M
Revenue Growth
-189.13%
P/S Ratio
0.28
Revenue / Employee
$140,440
Employees
384
Market Cap
15.07M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 53.93M | 3.43M | 6.78% |
Dec 31, 2022 | 50.50M | 2.51M | 5.23% |
Dec 31, 2021 | 47.99M | 1.10M | 2.34% |
Dec 31, 2020 | 46.89M | -7.92M | -14.44% |
Dec 31, 2019 | 54.81M | 8.28M | 17.80% |
Dec 31, 2018 | 46.53M | 8.50M | 22.35% |
Dec 31, 2017 | 38.03M | 8.91M | 30.60% |
Dec 31, 2016 | 29.12M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.66M |
Star Equity Holdings | 42.56M |
BIMI International Medical | 5.85M |
Immuron | 2.43M |
Talis Biomedical | 989.00K |
Talphera | 651.00K |
CNTG News
- 4 weeks ago - C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development - GlobeNewsWire
- 7 weeks ago - CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting - GlobeNewsWire
- 2 months ago - CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position - GlobeNewsWire
- 2 months ago - CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease - GlobeNewsWire
- 2 months ago - CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients - GlobeNewsWire
- 3 months ago - CENTOGENE Receives Nasdaq Non-Compliance Notice - GlobeNewsWire
- 4 months ago - CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders - GlobeNewsWire